Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H26N2O2 |
Molecular Weight | 326.4326 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2CC)[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34
InChI
InChIKey=LJOQGZACKSYWCH-LHHVKLHASA-N
InChI=1S/C20H26N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3/t13-,14-,19+,20-/m0/s1
Molecular Formula | C20H26N2O2 |
Molecular Weight | 326.4326 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24068450
http://www.ajtmh.org/content/s1-12/6/473.full.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24068450
http://www.ajtmh.org/content/s1-12/6/473.full.pdf
Hydroquinidine is a pharmaceutical agent that acts as a class I antiarrhythmic agent (Ia) in the heart. Hydroquinidine is a d-rotatory alkaloid derived from cinchiona bark. It is closely related to quinidine, differing from the latter alkaloid only in containing two more atoms of hydrogen in the molecule. The drug causes increased action potential duration, as well as a prolonged QT interval. It is not approved by FDA, but marketed in Spain, France, Italy and Pakistan under the brand names Lentoquine, Sérécor LP, Idrochinidina Lirca and Austacute, respectively. Like all other class I antiarrhythmic agents, Hydroquinidine primarily works by blocking the fast inward sodium current (INa). Hydroquinidine is also used for the treatment of Malaria.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869567 |
32.0 nM [IC50] | ||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Lentoquine Approved UseIndications: arrhythmias |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Hepatitis caused by quinidine. Study of a case and review of the literature]. | 1986 Mar |
|
Safety and effectiveness of oral quinidine in cardioversion of persistent atrial fibrillation. | 2001 Dec |
|
[Adverse drug reactions in three older patients, even without changes in medication]. | 2003 Mar 29 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1933143
Curator's Comment: Recordings were made from acutely dissociated melanotrophs, obtained following the enzymatic treatment and
mechanical disruption of the neuro-intermediate lobe of the
pituitary gland of the adult male rat
Halfmaximal inhibition of IK(f) at o mV occurred with 23 + 7.8uM
hydroquinidine
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:32:18 GMT 2023
by
admin
on
Fri Dec 15 17:32:18 GMT 2023
|
Record UNII |
8P68XPY4HG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C01BA13
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
757410
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
DTXSID50862110
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
100000077599
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
1435-55-8
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
m6113
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
8P68XPY4HG
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
91503
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
DB15300
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
889
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
SUB14136MIG
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
DIHYDROQUINIDINE
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | |||
|
27220
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
215-862-5
Created by
admin on Fri Dec 15 17:32:18 GMT 2023 , Edited by admin on Fri Dec 15 17:32:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |